Growth Metrics

Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $16.2 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity changed 0.45% to $16.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.2 billion through Dec 2025, up 6.83% year-over-year, with the annual reading at $16.2 billion for FY2025, 0.45% changed from the prior year.
  • Liabilities and Shareholders Equity hit $16.2 billion in Q4 2025 for Quest Diagnostics, roughly flat from $16.2 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $16.2 billion in Q4 2025 to a low of $12.8 billion in Q1 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $14.2 billion across 5 years, with a median of $13.7 billion in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 5.69% in 2022 and later increased 19.38% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $13.6 billion in 2021, then dropped by 5.69% to $12.8 billion in 2022, then grew by 9.23% to $14.0 billion in 2023, then increased by 15.2% to $16.2 billion in 2024, then grew by 0.45% to $16.2 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for DGX at $16.2 billion in Q4 2025, $16.2 billion in Q3 2025, and $16.0 billion in Q2 2025.